Company logo

NBRV - Nabriva Therapeutics plc

NASDAQ -> Healthcare -> Biotechnology
Dublin, Ireland
Type: Equity

NBRV price evolution
NBRV
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Current assets
Cash $20.16 $33.96 $47.83 $52.17
Short term investments $0.02 $0.02
Net receivables $12.36 $11.01 $12.75 $15.03
Inventory $15.54 $15.63 $14.51 $15.58
Total current assets $54.3 $65.2 $80.27 $88.41
Long term investments
Property, plant & equipment $0.21 $0.18 $0.23 $0.29
Goodwill & intangible assets $0.01 $0.02 $0.03 $0.04
Total noncurrent assets $0.6 $0.58 $0.64 $0.71
Total investments $0.02 $0.02
Total assets $54.89 $65.78 $80.91 $89.12
Current liabilities
Accounts payable $1.07 $1.58 $4.37 $1.48
Deferred revenue $0.37 $0.38
Short long term debt $6.62 $4.2 $3.77 $2.78
Total current liabilities $19.33 $16.27 $22.34 $19.73
Long term debt $0.51 $3.92 $4.26 $5.17
Total noncurrent liabilities $0.96 $4.88 $5.22 $6.11
Total debt $7.14 $8.11 $8.03 $7.95
Total liabilities $20.29 $21.16 $27.56 $25.83
Shareholders' equity
Retained earnings -$618.57 -$607.5 -$595.68 -$582.61
Other shareholder equity $0.03 $0.03 $0.03 $0.03
Total shareholder equity $34.6 $44.63 $53.35 $63.29
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $47.83 $41.59 $86.41 $102
Short term investments $0.02 $0.02 $0.17 $0.23
Net receivables $12.75 $4.28 $3.12 $4.3
Inventory $14.51 $5.82 $0.68
Total current assets $80.27 $57.22 $91.17 $108.75
Long term investments
Property, plant & equipment $0.23 $0.77 $2.47 $1.14
Goodwill & intangible assets $0.03 $0.08 $0.09 $0.1
Total noncurrent assets $0.64 $1.22 $2.94 $1.67
Total investments $0.02 $0.02 $0.17 $0.23
Total assets $80.91 $58.44 $94.11 $110.42
Current liabilities
Accounts payable $4.37 $2.89 $4.67 $3.3
Deferred revenue $0.37 $0.75
Short long term debt $3.77 $2.04
Total current liabilities $22.34 $18.52 $16.64 $17.81
Long term debt $4.26 $5.69 $34.5 $23.72
Total noncurrent liabilities $5.22 $6.78 $36.2 $23.98
Total debt $8.03 $7.73 $34.5 $23.72
Total liabilities $27.56 $25.3 $52.84 $41.79
Shareholders' equity
Retained earnings -$595.68 -$546.23 -$476.74 -$393.98
Other shareholder equity $0.03 $0.03 $0.03 $0.03
Total shareholder equity $53.35 $33.13 $41.27 $68.63
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Revenue
Total revenue $9.19 $8.02 $9.26 $8.86
Cost of revenue $4.46 $3.36 $5.27 $4.2
Gross Profit $4.74 $4.66 $4 $4.66
Operating activities
Research & development $4.09 $3.52 $2.39 $3.22
Selling, general & administrative $11.05 $12.7 $14.49 $12.26
Total operating expenses $15.13 $16.22 $16.88 $15.48
Operating income -$10.4 -$11.56 -$12.88 -$10.81
Income from continuing operations
EBIT -$10.49 -$11.25 -$12.89 -$10.68
Income tax expense $0.39 $0.35 -$0.05 -$0.25
Interest expense $0.2 $0.21 $0.22 $0.22
Net income
Net income -$11.07 -$11.82 -$13.06 -$10.65
Income (for common shares) -$11.07 -$11.82 -$13.06 -$10.65
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $28.89 $5.03 $9.48 $9.66
Cost of revenue $13.15 $0.77 $0.07
Gross Profit $15.75 $4.26 $9.41 $9.66
Operating activities
Research & development $12.63 $15.1 $26.41 $82.29
Selling, general & administrative $51.65 $55.28 $62.48 $41.74
Total operating expenses $64.28 $70.39 $88.9 $124.03
Operating income -$48.53 -$66.13 -$79.49 -$114.38
Income from continuing operations
EBIT -$48.06 -$67.61 -$79.02 -$114.6
Income tax expense $0.49 $0.14 $0.1 $0.05
Interest expense $0.9 $1.74 $3.64 $0.13
Net income
Net income -$49.45 -$69.48 -$82.76 -$114.78
Income (for common shares) -$49.45 -$69.48 -$82.76 -$114.78
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Net income -$11.07 -$11.82 -$13.06 -$10.65
Operating activities
Depreciation $0.08 $0.08 -$0.2 $0.08
Business acquisitions & disposals
Stock-based compensation $0.33 $1 $0.77 $0.78
Total cash flows from operations -$13.04 -$15.87 -$6.12 -$13.24
Investing activities
Capital expenditures -$0.06 -$0.04 -$0.01 $0
Investments
Total cash flows from investing -$0.12 -$0.04 -$0.01
Financing activities
Dividends paid
Sale and purchase of stock $0.4 $1.64 $2.45
Net borrowings -$0.55 $0.59 $4.31
Total cash flows from financing -$0.79 $2.19 $2.14 $4.07
Effect of exchange rate $0.15 -$0.16 -$0.35 $0.02
Change in cash and equivalents -$13.79 -$13.88 -$4.34 -$9.15
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$49.45 -$69.48 -$82.76 -$114.78
Operating activities
Depreciation $0.36 $0.82 $0.77 $0.51
Business acquisitions & disposals -$4.26
Stock-based compensation $3.29 $5.22 $9.75 $5.15
Total cash flows from operations -$59.56 -$71.33 -$71.89 -$72.72
Investing activities
Capital expenditures -$0.03 -$0.11 -$0.06 -$0.23
Investments -$0.12
Total cash flows from investing -$0.08 -$0.27 $0.33 -$4.6
Financing activities
Dividends paid
Sale and purchase of stock $27.91 $54.17 $20.51 $50
Net borrowings $42.28 -$22.48 $37.92 $49.75
Total cash flows from financing $66.37 $26.92 $56.08 $92.92
Effect of exchange rate -$0.48 -$0.14 -$0.11 -$0.36
Change in cash and equivalents $6.24 -$44.82 -$15.59 $15.23
Fundamentals
Market cap $160.16M
Enterprise value $147.13M
Shares outstanding 64.58M
Revenue $35.33M
EBITDA -$45.28M
EBIT -$45.32M
Net Income -$46.61M
Revenue Q/Q 11.50%
Revenue Y/Y 143.30%
P/E ratio -3.44
EV/Sales 4.16
EV/EBITDA -3.25
EV/EBIT -3.25
P/S ratio 4.53
P/B ratio 4.63
Book/Share 0.54
Cash/Share 0.31
EPS -$0.72
ROA -64.13%
ROE -95.18%
Debt/Equity 0.52
Net debt/EBITDA -0.00
Current ratio 2.81
Quick ratio 2.01